Healthy volunteers
Conditions
Interventions
Trade Name: Zyprexa (R)
Product Name: Olanzapine
Product Code: 090035
Pharmaceutical Form: Film-coated tablet
Trade Name: Zeldox (R)
Product Name: Ziprasidone
Product Code: 124364
Pharmaceutical Form
Sponsors
Department of General Psychiatry
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: - Age between 18-55 - Healthy male volunteers - No history of drug or alcohol abuse - No regular nicotine consumption at time of enrollment - Physical activity at least twice a week - Body mass Index between 19-24 kg/m2 - Normal laboratory values - Normotension (blood pressure less than 140/90) - No past or present history of psychiatric disorder - No family history of diabetes or obesity - Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Use of medication within the last 14 days - Consumption of alcohol within the last 5 days - Family history of diabetes or obesity - Past or present psychiatric disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the effects of treatment with the atypical antipsychotics olanzapine and ziprasidone in steady-state conditions on the arterial to interstital skeletal muscle gradient for glucose in human skeletal muscle during euglycaemic hyperinsulinaemic clamp conditions in male healthy volunteers.;Secondary Objective: ;Primary end point(s): The arterial to interstitial skeletal muscle glucose gradient before and during euglycaemic hyperinsulinaemic clamp conditions. This gradient will be measured before and after administration of 10 mg olanzapine or 80 mg ziprasidone in steady-state conditions. Endpoint will be set after second euglycaemic hyperinsulinaemic clamp and microdialysis. | — |
Countries
Austria
Outcome results
None listed